1. Stocks
    2. /
  2. Mesoblast Limited (ASX: MSB)
    3. /

Mesoblast Limited (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Mesoblast Limited (ASX: MSB)
    Latest News

    A man sits thoughtfully on the couch with a laptop on his lap.
    Broker Notes

    15 ASX All Ords shares upgraded to 'strong buy' status for the new financial year

    | Bronwyn Allen

    Looking for investment inspiration for the new financial year?

    Read more »

    Hands reaching high for a trophy with a sunset in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a nervous hump day session for ASX investors today.

    Read more »

    Cropped shot of an attractive young female scientist working on her computer in the laboratory.
    Healthcare Shares

    Why is the Mesoblast share price up 11% in June?

    | Bronwyn Allen

    The ASX biotech share reached a 10-week high of $1.94 today.

    Read more »

    Person pretends to types on laptop drawn in sand.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors managed to ease out a gain from the markets today.

    Read more »

    Businessman smiles with arms outstretched after receiving good news.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a lucrative return to trading for investors this Tuesday.

    Read more »

    A young woman smiles as she rides a zip line high above the trees.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a bountiful session for investors this hump day.

    Read more »

    The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors panicked when the latest inflation figures came out today.

    Read more »

    A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
    Broker Notes

    These ASX 200 shares could rise 20% to 100%

    | James Mickleboro

    Analysts are expecting these shares to deliver big returns over the next 12 months.

    Read more »

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was the ASX's fourth day of gains for the week today.

    Read more »

    Ten happy friends leaping in the air outdoors.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a great end to the week's trading today...

    Read more »

    A woman's hand draws a stylised 'Top Ten' on a projected surface.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors kept up the positive momentum this Tuesday.

    Read more »

    Person pretends to types on laptop drawn in sand.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    Investors were off to a flying start this Monday.

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Limited

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    Profile

    since

    Note